Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cronos Group, Inc. (NASDAQ: CRON).

Full DD Report for CRON

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-186.045.806.145.762,382,995
2018-05-176.045.806.145.762,382,995

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-121,413,8122,894,13648.8509Short
2018-12-111,497,6402,740,28554.6527Short
2018-12-103,434,3205,521,26962.2016Short
2018-12-077,160,56513,352,65953.6265Short
2018-12-061,824,8323,142,58758.0678Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CRON.


About Cronos Group, Inc. (NASDAQ: CRON)

Logo for Cronos Group, Inc. (NASDAQ: CRON)

Cronos Group, is a geographically diversified and vertically integrated cannabis company that operates two wholly owned Licensed Producers LPs regulated within Health Canada s Access to Cannabis for Medical Purposes Regulations the ACMPR and holds a portfolio of minority investments in other Licensed Producers.

 

Contact Information

 

 

Current Management

  • Michael Gorenstein / President, CEO
    • Before joining Cronos, Mr. Gorenstein was a partner at Alphabet Ventures LLC, a multistrategy investment management firm located in New York City. Prior to Alphabet Management, Michael was the VP and General Counsel of Saiers Capital LLC and a corporate attorney at Sullivan amp Cromwell where he focused on Mergers and Acquisitions and Capital Market transactions. Michael graduated from the University of Pennsylvania Law School with a JD, the Wharton School at University of Pennsylvania with a certificate in BEPP and the Kelley School of Business at Indiana University with a BSB in Finance.
  • William Hilson / CFO
    • Mr. Hilson is a Certified Public Accountant CPA and has spent over years as regional CFO for two publicly listed multinational pharmaceutical companies Merck KGaA and Serono S.A. His expertise includes financial operations, strategy, performance management, sales amp marketing, clinical trial management, international tax, debt amp equity financing including a NASDAQ initial public offering. Prior to joining Cronos Group, William was also involved in a number of mergers amp acquisitions and licensing deals in the pharmaceutical sector. He earned his CPA designation while working at a Toronto firm specializing in tax structure. He graduated from the University of Toronto and The University of Western Ontario where he earned a Master of Science degree in Clinical Biochemistry and an Honours Bachelor of Genetics. An accomplished researcher at the Hospital For Sick Children, William has published abstracts and peer reviewed papers in international journals. William also holds an Audit Committee Board Member designation from The Directors College, McMaster University.
  • Michael Gorenstein / Chairman
    • Before joining Cronos, Mr. Gorenstein was a partner at Alphabet Ventures LLC, a multistrategy investment management firm located in New York City. Prior to Alphabet Management, Michael was the VP and General Counsel of Saiers Capital LLC and a corporate attorney at Sullivan amp Cromwell where he focused on Mergers and Acquisitions and Capital Market transactions. Michael graduated from the University of Pennsylvania Law School with a JD, the Wharton School at University of Pennsylvania with a certificate in BEPP and the Kelley School of Business at Indiana University with a BSB in Finance.
  • Jason Adler / Director
    • Jason is the CEO and Managing Member of Alphabet Ventures, LLC, a captive investment vehicle operating in a wide range of domains including growth equity, established companies with growth perspective, and creative debt vehicles. Prior to Alphabet Ventures Jason was the cofounder and CEO of Alphabet Management, LLC, a New York based volatility fund, that focused on identifying mispriced assets across various industries, asset classes and geographies. Jason also founded Geronimo, LLC, an AMEX member broker dealer that made markets in equity options, and he began his career as a market maker at G amp D Trading, an AMEX member market maker. Jason received his B.A. from the University of Rhode Island.
  • Alan Friedman / Director
    • Currently President, Cofounder amp Director of Osino Resources, a private Gold company with assets in Africa. Alan is an Africantrained lawyer and public markets entrepreneur. Involved with North American public markets for more than years. Played integral role in acquisitions, financings amp gopublic transactions for many resource companies onto TSX and AIM. Cofounder amp Director of TSXV listed Eco Atlantic Oil and Gas Ltd. and Auryx Gold Corp. Director of the CanadaSouthern Africa Chamber of Business.
  • Michael Krestell / Director
    • Mr. Krestell has been the President of M Partners Inc. since and prior thereto he was the firm s Managing Director of Equity Research. Mr. Krestell received a Starmine award by being the number ranked stock picker in Canada in . He received an MBA with distinction from the Schulich School of Business and is a CFA charterholder.

Current Share Structure

  • Market Cap: $879,899,799 - 05/11/2018
  • Issue and Outstanding: 143,774,477 - 10/25/2017

 


Recent Filings from (NASDAQ: CRON)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 15 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 09 2018
Registration of a class of securities of certain Canadian issuers under Section 12(b) of the 1934 Act
Filing Type: 40-FFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 30 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 06 2018
Amendment to a previously filed F-10
Filing Type: F-10/AFiling Source: edgar
Filing Date: March, 29 2018

 

 


Daily Technical Chart for (NASDAQ: CRON)

Daily Technical Chart for (NASDAQ: CRON)


Stay tuned for daily updates and more on (NASDAQ: CRON)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CRON)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CRON is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CRON and does not buy, sell, or trade any shares of CRON. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/